Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
221 results about "Aminoglycoside" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside (sugar). The term can also refer more generally to any organic molecule that contains amino sugar substructures. Aminoglycoside antibiotics display bactericidal activity against Gram-negative aerobes and some anaerobic bacilli where resistance has not yet arisen but generally not against Gram-positive and anaerobic Gram-negative bacteria.
Pulmonary delivery of aminoglycosides
InactiveUS7368102B2Eliminate side effectsReduce in quantityBiocidePowder deliveryRespiratory infectionTopical treatment
The present invention is directed to the administration of aminoglycosides. In particular, the present invention is directed to compositions and methods for the pulmonary administration of aminoglycosides. According to a preferred embodiment, compositions and methods are provided for the localized treatment of respiratory infections.
Owner:BGP PROD OPERATIONS GMBH +1
Compositions containing pipercillin and tazobactam useful for injection
InactiveUS6900184B2Reduce formationMaintain stabilityBiocidePeptide/protein ingredientsParticulatesDepressant
The invention pertains to pharmaceutical compositions of Zosyn® piperacillin with tazobactam in the presence of a buffer, preferably citrate, a particulate formation inhibitor, preferably EDTA optionally an aminoglycoside which when frozen and thawed or lyophilized and reconstituted reform a solution which has decreased particulate formation.
Owner:MEDICAL SAFETY PROD
Compositions of nucleic acids and cationic aminoglycosides and methods of using and preparing the same
InactiveUS20050019926A1High transfection efficiencyAntibacterial agentsPowder deliveryPolymerAminoglycoside Agents
Compositions that include nucleic acid and cationic aminoglycosides and methods for their use are provided. The subject compositions are characterized by having nucleic acid complexed with a cationic aminoglycoside, where the nucleic acid is condensed. In certain embodiments, the cationic aminoglycoside is a cationic aminoglycoside antibiotic. The composition may further include one or more of: functional groups such as targeting moieties, nuclear localization or targeting peptides, endosomolytic peptides and / or one or more lipids and / or polymers, where the lipids may be provided in a manner to encapsulate the nucleic acid. The present invention also provides methods of using and preparing the nucleic acid-aminoglycoside compositions.
Owner:ARADIGM
Therapy for enteric infections
There is disclosed herein a composition for treating gastrointestinal or neurological disorders, constipation, functional constipation, irritable bowel syndrome, diverticulitis, travelers diarrhea, chronic idiopathic nausea, IBD-associated constipation and diarrhea, pseudo-obstruction, diabetic gastroparesis, cyclic vomiting, reflux oesophagitis, autism enteropathy, flatulence, halitosis, chronic fatigue, bloating, proctalgia fugax, Parkinsons disease, MS, Alzheimers Disease, Motor Neurone Disease or autism, the composition comprising: (i) at least two anti-clostridial agents selected from the group consisting of: vancomycin, vancomycin derivatives, a multi-valent polymer of vancomycin, aminoglycosides, nitroimidazoles, ansamysins, nifuroxazide, colchicine, prucalopride, prokinetic agent and 5-aminosalicylic acid; or (ii) at least one anti-clostridial agent selected from the above combined with an opioid blocking agent. There is also disclosed herein a method of treating various gastrointestinal or neurological disorders, constipation, functional constipation, irritable bowel syndrome, diverticulitis, travelers diarrhea, chronic idiopathic nausea, IBD-associated constipation and diarrhea, pseudo-obstruction, diabetic gastroparesis, cyclic vomiting, reflux oesophagitis, autism enteropathy, flatulence, halitosis, chronic fatigue, bloating, proctalgia fugax, Parkinsons disease, MS, Alzheimers Disease, Motor Neurone Disease or autism, the method comprising administering orally, via enema or by suppository: (i) a composition of the invention; (ii) at least two anti-clostridial agents selected from the group consisting of: vancomycin, vancomycin derivatives, a multi-valent polymer of vancomycin, aminoglycosides, nitroimidazoles, ansamysins, nifuroxazide, colchicine, prucalopride, prokinetic agent and 5-aminosalicylic acid; or (iii) at least one anti-clostridial agent selected from the above and an opioid blocking agent to a patient in need of such treatment.Owner:BORODY THOMAS JULIUS
Antibacterial 4,5-substituted aminoglycoside analogs having multiple substituents
The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection.
Owner:IONIS PHARMA INC
Stable pharmaceutical compositions of aminoglycoside antibiotics, ion-chelating agents, and buffers
InactiveUS20090156517A1Reduce formationMeet the requirementsAntibacterial agentsBiocideParticulatesAntibiotic Y
A pharmaceutical composition comprising: at least one aminoglycoside antibiotic and (a) at least one ion chelating agent used for inhibiting particulate formation, or (b) at least one buffer, or (c) at least one ion chelating agents and at least one buffer simultaneously. The composition for use in controlling microbial infection can be formulated into a solution, or combined with at least one beta-lactam antibiotic, or combined with at least one of beta-lactam antibiotic and at least one beta-lactamase inhibitor into a solution in a container.
Owner:ZHANG HESHENG
Aminoglycoside treatment for lysosomal storage diseases
ActiveUS20050153906A1Effective treatmentHigh activityBiocideSugar derivativesLysosomal enzyme defectHurler syndrome
The present invention provides a method of treating lysosomal storage diseases such as Hurler syndrome and Batten disease in individuals in need of such treatment, comprising the step of administering to said individuals a therapeutically effective dose of an aminoglycoside. In addition, this method may further comprise treating the individual with enzyme replacement therapy. Furthermore, the present invention provides method of pharmacologically suppressing premature stop mutations in an individual with these lysosomal storage diseases, comprising the step of administering to said individual a pharmacologically effective dose of an aminoglycoside.
Owner:UAB RES FOUND
Compositions of nucleic acids and cationic aminoglycosides and methods of using and preparing the same
InactiveUS20030096774A1Effectively tranfect complexesHigh transfection efficiencyAntibacterial agentsPowder deliveryOrganic chemistryAntibiotic drug
Compositions that include nucleic acid and cationic aminoglycosides and methods for their use are provided. The subject compositions are characterized by having nucleic acid complexed with a cationic aminoglycoside, where the nucleic acid is condensed. In certain embodiments, the cationic aminoglycoside is a cationic aminoglycoside antibiotic. The composition may further include one or more of: functional groups such as targeting moieties, nuclear localization or targeting peptides, endosomolytic peptides and / or one or more lipids and / or polymers, where the lipids may be provided in a manner to encapsulate the nucleic acid. The present invention also provides methods of using and preparing the nucleic acid-aminoglycoside compositions.
Owner:ARADIGM
Bifunctional antibiotics for targeting rRNA and resistance-causing enzymes
InactiveUS20050004052A1High activityOvercome resistanceBiocideSugar derivativesAntibiotic resistanceAntibiotic Y
A novel group of aminoglycosides which share some structural features of currently available aminoglycosides with regard to the backbone, while also having significant structural differences. The similarity enables these aminoglycosides to be highly potent and effective antibiotics, while the significant differences enable these aminoglycosides to reduce or even block antibiotic resistance.
Owner:TECHNION RES & DEV FOUND LTD
Combination of nordihydroguaiaretic acid and an aminoglycoside
InactiveUS20160038438A1Shorten chemotherapy regimeReduce problemsAntibacterial agentsBiocideMicroorganismMicrobiology
The present invention relates to the use of a combination of nordihydroguaiaretic acid and an aminoglycoside for treating a microbial infection or for killing clinically latent microorganisms associated with microbial infections.
Owner:HELPERBY THERAPEUTICS LTD
Antibacterial 1,4,5-substituted aminoglycoside analogs
The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection.
Owner:ACHAOGEN
Antibacterial 6'-modified 4,5-substituted aminoglycoside analogs
The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection.
Owner:IONIS PHARMA INC
Pharmaceutical compositions and use thereof
InactiveUS20090169635A1Efficient curingIncrease loopAntiinfectivesGranular deliveryAntibacterial activityAntibiotic Y
Colloidal compositions, loaded with non-covalently bonded antibiotics, can be efficiently used for the treatment of severe bacterial pneumonia and other serious lung infections such as tuberculosis. Such formulations, comprised of biodegradable nanoparticles or nanocapsules with incorporated antibiotics, show a significant increase in antibacterial activity, extended and sustained drug release and a decrease in frequency of the drug administration. Antibiotics of various types, such as aminoglycosides, glycopeptides and others can be successfully incorporated into a nanoparticulate colloidal delivery system.
Owner:ALPHARX
Compositions containing piperacillin and tazobactam useful for injection
An aminocarboxylic acid chelating agent, preferably EDTA, or a salt thereof has been found to be useful for inhibiting particulate formation in piperacillin / tazobactam parenteral combinations. The composition may also contain a buffer, preferably citrate, and optionally an aminoglycoside. The product may be in the form of a frozen composition that can be thawed for use. The product may also be in the form of a cryodesiccated powder that can be reconstituted by addition of an aqueous vehicle to reform a solution.Owner:BAXTER HEALTCHARE CORP
Antibacterial 4,5-substituted aminoglycoside analogs having multiple substituents
The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection.
Owner:IONIS PHARMA INC
Method of preparing 4-R-substituted 4-demethoxydaunorubicin
ActiveUS7053191B2Reduce in quantityImprove processing yieldSugar derivativesSugar derivatives preparationPtru catalystAcyl group
A method of synthesizing 4-R-substituted anthracyclines and their corresponding salts from 4-demethyldaunorubicin includes the steps of treating 4-demethyldaunorubicin with a sulfonylating agent to form 4-demethyl-4-sulfonyl-R3-daunorubicin. 4-Demethyl-4-R3-sulfonyl-daunorubicin is then subject to a reducing agent in the presence of a transition metal catalyst in a temperature range of about 30° C. to about 100° C. in a polar aprotic solvent in an inert atmosphere. Protected 4-demethoxy-4-R-daunomycin then undergoes hydrolysis in a basic solution to form the 4-R-substituted anthracyclines. The novel method lacks the step of forming a stereospecific glycoside bond between aglycone and aminoglycoside. The method also increases the yield of the final product up to 30 to 40%.
Owner:SYNBIAS PHARMA
Stable pharmaceutical composition comprising beta-lactam antibiotic and ion-chelating agent
InactiveUS20090155387A1Reduce formationAvoid drug resistanceAntibacterial agentsBiocideMedicineAntibiotic Y
A pharmaceutical composition comprising: at least one β-lactam antibiotic and at least one ion-chelating agent; wherein when said pharmaceutical composition is used as an anti-microbial drug, it optionally comprises further at least one aminoglycoside antibiotic.Owner:ZHANG HESHENG
Antibacterial aminoglycoside analogs
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I):
including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Z1, Z2, Z3, Z4, R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
Owner:ACHAOGEN
Nonsense suppressor agents in treatment of cutaneous and gastrointestinal disorders
InactiveUS20050261210A1Suppresses genetic basisAdverse side-effectBiocideCarbohydrate active ingredientsDiseaseSuppressor
The invention features methods of treating a inherited or acquired cutaneous or gastrointestinal (GI) disorder caused by or having a symptom caused by a nonsense mutation by local administration of a nonsense suppressor agent (e.g., an aminoglycoside or nucleic acid encoding a suppressor tRNA) to the skin or intraluminal GI surface so as to provide for phenotypic suppression of the nonsense mutation.
Owner:RGT UNIV OF CALIFORNIA
Aminoglycosides and uses thereof in treating genetic disorders
ActiveUS8895519B2High premature stop-codon mutations read-through activityLow toxicityBiocideMuscular disorderCytotoxicityHigh selectivity
A new class of pseudo-trisaccharide aminoglycosides having an alkyl group at the 5″ position, exhibiting efficient stop codon mutation readthrough activity, low cytotoxicity and high selectivity towards eukaryotic translation systems are provided. Also provided are pharmaceutical compositions containing the same, and uses thereof in the treatment of genetic disorders, as well as processes of preparing these aminoglycosides. The disclosed aminoglycosides can be represented by the general formula I:or a pharmaceutically acceptable salt thereof, wherein R1 is selected from the group consisting of alkyl, cycloalkyl and aryl; and all other variables and features are as described in the specification.
Owner:TECHNION RES & DEV FOUND LTD
Antibacterial aminoglycoside analogs
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I):including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q3, R1, R2 or R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
Owner:CIPLA USA INC
Antibacterial aminoglycoside analogs
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I):
including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q3, R8 and R9 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
Owner:CIPLA USA INC
Antibacterial aminoglycoside analogs
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I):including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q3, R8 and R9 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
Owner:CIPLA USA INC
Compositions and methods for antibiotic potentiation and drug discovery
The present invention provides methods for identifying target genes whose partial or complete functional inactivation potentiates the activity of an antibiotic agent, e.g., a quinolone antibiotic. The invention further provides methods for identifying agents that modulate expression of target genes or that modulate activity of expression products of target genes. Agents identified according to various methods of the invention potentiate the activity of antibiotics such as quinolones, aminoglycosides, peptide antibiotics and β-lactams. Also provided are agents that suppress and / or retard resistance to antibiotics. The inventive methods provide potentiating agents and compositions comprising potentiating agents and antibiotics. Such agents and compositions can be used for inhibiting growth or survival of a microbial cell or of treating a subject suffering from or susceptible to a microbial infection.
Owner:TRUSTEES OF BOSTON UNIV
Antibacterial aminoglycoside analogs
InactiveUS20110288041A1Stable genetic changeAntibacterial agentsBiocideStereoisomerismStereochemistry
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I):
including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
Owner:ACHAOGEN
Antibacterial aminoglycoside analogs
InactiveUS20120122809A1Stable genetic changeAntibacterial agentsBiocideAntibacterial activityStereoisomerism
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I):
including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein Q1 and Q2 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
Owner:ACHAOGEN
Antibacterial aminoglycoside analogs
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I):
including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q3, R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
Owner:CIPLA USA INC
Antibacterial aminoglycoside analogs
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I) or (II):
including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q3, R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
Owner:CIPLA USA INC
Antibacterial aminoglycoside analogs
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I):
including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
Owner:ACHAOGEN
Antibacterial aminoglycoside analogs
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I) or (II):
including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q3, R1, R2, R3, R11 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
Owner:CIPLA USA INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Try Eureka
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap